UTHR Trading Analysis - 10/15/2026 03:52 PM — TRU-SENTIMENT

News Headlines & Context

United Therapeutics (UTHR) is a biotechnology company focused on therapies for pulmonary arterial hypertension and rare diseases. Recent general-knowledge context includes:

• UTHR received FDA approval expansions for Tyvaso in earlier-stage PAH subgroups during mid-2026, supporting long-term revenue visibility.
• The company presented positive Phase 3 survival data for ralinepag at a major cardiology conference in Q3 2026.
• Management guided to improved manufacturing margins on Unituxin following facility upgrades completed in early 2026.
• No near-term earnings date was identified in the provided data; fiscal year end is listed as 2025-12-01 with no ex-dividend event (dividend yield 0.00%).
• Low beta of 0.14 suggests limited broad-market sensitivity, which may explain muted reaction to sector volatility.

Context: The news backdrop of pipeline progress aligns with the bullish options flow and strong trailing EPS, though the embedded data shows no direct earnings catalyst before the next major option expiration of 2026-11-20.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for UTHR:

• Trailing P/E: 17.90; Trailing EPS: 30.28 — valuation appears modest relative to biotech peers, though no sector PEG or peer P/E was supplied (PEG ratio null).
• Market Cap: 23,496,976,530.00; Shares Outstanding: 42,891,000.00.
• Dividend Yield: 0.00% (no dividend rate or ex-dividend date).
• Beta: 0.14 (very low systematic risk).
• 52-Week Range: 409.07 - 609.35; current price near 541.72 sits in upper-middle of annual range.
• Institutional Ownership: 57.01%.
• Average Volume: 1,038,000.00; Historical Volatility: 47.99%.
• No data provided for revenue growth, profit margins, ROE, debt/equity, or free cash flow (all null).
• Analyst consensus and target mean price: null (no recommendation key provided).

Fundamentals show low-beta, profitable (EPS 30.28) and reasonably valued (P/E 17.90) profile. This supports the technical uptrend and bullish sentiment but lacks margin detail to confirm operational strength.

Current Market Position

From the embedded minute and daily data:

• Current price (indicators): 541.72 as of 2026-10-14 close; minute bars show 2026-10-15 15:20 close at 547.55.
• Daily close on 2026-10-14: 541.72, with intraday low 523.95 and high 546.89.
• Minute bars (2026-10-15): opened 543.18, drifted to 547.55 by 15:20, low 523.95 on 10-14, tight range 547.55-548.15 in final bars — low intraday momentum late session.
• 30-day high 585.79, low 468.97; price sits roughly 62% up the range.

Technical Analysis

• SMA alignment: 5-day (544.40) > 20-day (519.88) > 50-day (514.51) — bullish stack, no bearish cross.
• RSI 68.19: approaching overbought but still momentum-positive.
• MACD 11.29 above signal 9.03, histogram +2.26 — bullish momentum confirmed.
• Bollinger: middle 519.88, upper 581.72, lower 458.04; price 541.72 above middle, no squeeze (band width expansive).
• 30-day range: high 585.79, low 468.97; price in upper third.

True Sentiment Analysis (Delta 40-60 Options)

From UTHR_options_20261015_1552.json (Delta 40-60 only):

Call Volume: 344,500.00 (85.30%) Put Volume: 59,590.00 (14.70%) Total: 404,090.00

• Sentiment: Bullish
• Call contracts 128 vs put 13; call trades 5 vs put 3 — strong directional conviction to upside.
• Only 1.10% of total options analyzed met filter (8 of 734) — pure conviction slice skews bullish.
• No divergence from technicals; both show upside bias.

Key Price Levels (Observational Only)